Sagittarius Life Science (3205) - Total Assets
Based on the latest financial reports, Sagittarius Life Science (3205) holds total assets worth NT$1.11 Billion TWD (≈ $35.09 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Sagittarius Life Science (3205) shareholders funds for net asset value and shareholders' equity analysis.
Sagittarius Life Science - Total Assets Trend (2015–2024)
This chart illustrates how Sagittarius Life Science's total assets have evolved over time, based on quarterly financial data.
Sagittarius Life Science - Asset Composition Analysis
Current Asset Composition (December 2024)
Sagittarius Life Science's total assets of NT$1.11 Billion consist of 48.3% current assets and 51.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 16.1% |
| Accounts Receivable | NT$43.33 Million | 8.3% |
| Inventory | NT$31.05 Million | 6.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Sagittarius Life Science's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sagittarius Life Science stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sagittarius Life Science's current assets represent 48.3% of total assets in 2024, a decrease from 85.9% in 2015.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2024, down from 37.2% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 8.3% of total assets.
Sagittarius Life Science Competitors by Total Assets
Key competitors of Sagittarius Life Science based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sagittarius Life Science - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.01 | 2.67 | 4.03 |
| Quick Ratio | 14.89 | 2.35 | 3.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$801.04 Million | NT$164.71 Million | NT$381.60 Million |
Sagittarius Life Science - Advanced Valuation Insights
This section examines the relationship between Sagittarius Life Science's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -21.8% |
| Total Assets | NT$519.83 Million |
| Market Capitalization | $119.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sagittarius Life Science's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sagittarius Life Science's assets decreased by 21.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sagittarius Life Science (2015–2024)
The table below shows the annual total assets of Sagittarius Life Science from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$519.83 Million ≈ $16.38 Million |
-21.80% |
| 2023-12-31 | NT$664.72 Million ≈ $20.94 Million |
+14.78% |
| 2022-12-31 | NT$579.12 Million ≈ $18.25 Million |
-14.30% |
| 2021-12-31 | NT$675.75 Million ≈ $21.29 Million |
-8.77% |
| 2020-12-31 | NT$740.74 Million ≈ $23.34 Million |
-8.73% |
| 2019-12-31 | NT$811.59 Million ≈ $25.57 Million |
-9.19% |
| 2018-12-31 | NT$893.75 Million ≈ $28.16 Million |
-15.89% |
| 2017-12-31 | NT$1.06 Billion ≈ $33.48 Million |
-24.77% |
| 2016-12-31 | NT$1.41 Billion ≈ $44.50 Million |
+24.81% |
| 2015-12-31 | NT$1.13 Billion ≈ $35.65 Million |
-- |
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.